RT Journal Article
SR Electronic
T1 Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression
JF Cancer Immunology Research
JO Cancer Immunol Res
FD American Association for Cancer Research
SP 1407
OP 1425
DO 10.1158/2326-6066.CIR-20-0264
VO 8
IS 11
A1 Silva, Mariana C.
A1 Fernandes, Ângela
A1 Oliveira, Maria
A1 Resende, Carlos
A1 Correia, Alexandra
A1 de-Freitas-Junior, Julio C.
A1 Lavelle, Aonghus
A1 Andrade-da-Costa, Jéssica
A1 Leander, Magdalena
A1 Xavier-Ferreira, Helena
A1 Bessa, José
A1 Pereira, Carina
A1 Henrique, Rui M.
A1 Carneiro, Fátima
A1 Dinis-Ribeiro, Mário
A1 Marcos-Pinto, Ricardo
A1 Lima, Margarida
A1 Lepenies, Bernd
A1 Sokol, Harry
A1 Machado, José C.
A1 Vilanova, Manuel
A1 Pinho, Salomé S.
YR 2020
UL http://cancerimmunolres.aacrjournals.org/content/8/11/1407.abstract
AB Tumor growth is accompanied with dramatic changes in the cellular glycome, such as the aberrant expression of complex branched N-glycans. However, the role of this protumoral N-glycan in immune evasion and whether its removal contributes to enhancement of immune recognition and to unleashing an antitumor immune response remain elusive. We demonstrated that branched N-glycans are used by colorectal cancer cells to escape immune recognition, instructing the creation of immunosuppressive networks through inhibition of IFNγ. The removal of this “glycan-mask” exposed immunogenic mannose glycans that potentiated immune recognition by DC-SIGN–expressing immune cells, resulting in an effective antitumor immune response. We revealed a glycoimmune checkpoint in colorectal cancer, highlighting the therapeutic efficacy of its deglycosylation to potentiate immune recognition and, thus, improving cancer immunotherapy.